Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide

• DOI: 10.1007/s00277-023-05206-5
• Publication Date: 2023-04-21T07:03:16Z
• Authors: Ignacio Gómez-Cen...; Reyes Maria Marti...; Rebeca Bailén; Cristina Muñoz; Santiago Sabell; Gillen Oarbeascoa; Paula Fernández-C...; Diego Carbonell; Jorge Gayoso; Carolina Martínez...; Ismael Buño; Javier Anguita; José Luis Díez-Ma...; Mi Kwon
• Keywords: Adult; Transplantation Conditioning; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Graft vs Host Disease; Cyclophosphamide; Retrospective Studies

This is a retrospective cohort study of consecutive adult patients who received a haploidentical-SCT (haplo-SCT) with post-transplant cyclophosphamide (PT-Cy) in a single centre. Poor graft function (PGF) was defined as the occurrence of either persistent neutropenia (ANC < 0.5 × 109/µL) with poor response to granulocyte colony-stimulating factors (G-CSF) and/or thrombocytopenia (platelets < 20 × 109/L) with transfusion dependence, with complete donor chimerism and without concurrent severe GVHD or underlying disease relapse, during the first 12 months after transplantation. Forty-four (27.5%) out of 161 patients were diagnosed with PGF. Previous CMV reactivation was significantly more frequent in patients with PGF (88.6% versus 73.5%, p = 0.04) and the number of reactivations was also higher in these patients. Besides, early CMV reactivations in the first 6 months post-SCT were also significantly more frequent among patients with PGF (88.6% versus 71.8% p = 0.025). Thirty-two percent of patients with PGF were treated with increasing doses of thrombopoietin-receptor agonists (TRA) and 7 patients were treated with a donor CD34 + selected boost. In total, 93.2% of patients reached adequate peripheral blood counts in a median time of 101 days (range 11-475) after diagnosis. PGF is a frequent complication after haplo-SCT with PT-Cy. CMV reactivation might be the most relevant factor associated to its development. Even when most patients recover peripheral counts with support therapy, there is a group of patients with persistent cytopenias who can effectively be treated with TRA and/or a boost of CD34 + selective cells.